EP Patent

EP1435240A2 — Solid oral dosage form comprising a combination of methformin and glibenclamide

Assigned to Merck Sante SAS · Expires 2004-07-07 · 22y expired

What this patent protects

Pharmaceutical composition comprising a single solid oral dosage form containing an effective dose of metformin and an effective dose of glibenclamide wherein, after oral administration thereof to a human, the bioavailibility of glibenclamide is comparable to the bioavailability …

USPTO Abstract

Pharmaceutical composition comprising a single solid oral dosage form containing an effective dose of metformin and an effective dose of glibenclamide wherein, after oral administration thereof to a human, the bioavailibility of glibenclamide is comparable to the bioavailability of glibenclamide achieved by oral administration of separate solid oral dosage forms to a human, one containing glibenclamide and the other metformin, in the same respective effective doses as in said single oral dosage form.

Drugs covered by this patent

Patent Metadata

Patent number
EP1435240A2
Jurisdiction
EP
Classification
—
Expires
2004-07-07
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sante SAS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.